Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Active substance : fosinopril
  • Active substance : trastuzumab
  • Type : Practice Guidelines and Other Guides
Filter
Topic
  • Diseases and conditions (1)
  • Plus ...
    • Heart diseases (1)
    • Plus ...
      • Heart failure (1)
Content type
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Chronic disease guide (1)
Date
  • Last five years (1)
Language
  • Français (1)
Active substance
  • alcool (1)
  • apixaban (1)
  • aspirine (1)
  • cibenzoline (1)
  • cilazapril (1)
  • disopyramide (1)
  • fosinopril (1)
  • lithium (1)
  • losartan (1)
  • potassium (1)
  • ramipril (1)
  • rivaroxaban (1)
  • spironolactone (1)
  • trastuzumab (1)
  • tyrosine (1)

Practice Guidelines and Other Guides

  • « Première page
  • < Page précédente
  • / 1
  • > Page suivante
  • » Dernière page
Sorted by :Relevance
  • Title
  • Date

  • Symptomatic chronic systolic heart failure

    Chronic disease guide - Posted on 24/07/2015
    Add to my selection
  • « Première page
  • < Page précédente
  • / 1
  • > Page suivante
  • » Dernière page
  • 10 par pages
    • 10 par pages
    • 20 par pages
    • 50 par pages
    • 100 par pages
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
pkNJ79HSwCChRb4Q